Dr. Emri Seli, March of Dimes Chief Scientific Officer and Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine discusses the March of Dimes‘ increased focus on recurrent pregnancy loss (RPL) and the work March of Dimes researchers will perform to gather new insights into RPL through the lens of environmental factors.
INTERVIEWS
New Research Shows How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer
Dr. Nicholas Robert, CMO of Ontada, discusses new research that examines potential factors that may impact care and outcomes for affected communities with a common and aggressive form of cancer, Triple Negative Breast Cancer.
3M’s Tech Innovations are Combating Clinician Burnout
Dr. Ron Silverman, MD, Senior Vice President, Global Medical and Clinical Affairs and Chief Medical Officer at 3M discusses how the company’s AI and automation technology has helped healthcare providers increase efficiency and focus more on patient care. To reduce physician burnout and streamline processes, 3M has developed software and services to help identify, prioritize, and address documentation gaps in real-time that can impact care, quality, and financial success with AI-powered CDI and integrated CAPD. 3M CDI Engage One uses encounter-based clinical reasoning and automation to analyze EHR notes and narrative documents in real-time to help close gaps in patient care and clinical documentation.
LEQEMBI ® (lecanemab-irmb) Now Approved Via Traditional U.S FDA Review
Returning guest, Dr. Michael Irizarry, Senior Vice President and Deputy Chief Clinical Officer, Alzheimer’s Disease and Brain Health, at Eisai Inc. discusses the U.S. Food and Drug Administration’s (FDA) traditional approval of LEQEMBI ® (lecanemab-irmb) 100 mg/mL injection for intravenous use as the first and only disease-modifying treatment for Alzheimer’s disease (AD).
New Data Demonstrates Potential for Oral IL-23 in Psoriasis
Dr. Laura Korb Ferris, MD, PhD, Professor, University of Pittsburgh Clinical and Translational Science Institute and Director of Clinical Trials, UPMC Department of Dermatology discusses the new phase 2b FRONTIER 1 study data that demonstrates the potential of JNJ-2113, the novel first and only oral IL-23 antagonist peptide to “potentially change the treatment paradigm” for patients with moderate to severe plaque psoriasis. She talks about why this data may be encouraging for patients and prescribers.
The Challenges and Rewards of Growing Up with Three Autistic Brothers
Ali Carbone, sister to three brothers with autism, discusses her new memoir called “What Are You Looking At?” Ali shares her firsthand perspective and gives light to the untold stories of siblings with intellectual and developmental disabilities (IDD).
ASCO 2023 – AstraZeneca – Positive Results from ADAURA Phase III Trial
Returning guest, Dr. Roy Herbst, MD, PhD, from the Yale School of Medicine and primary investigatory of the ADAURA Phase III trial discusses the positive results that show TAGRISSO ® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), with 88% of patients alive at five years compared to placebo in the adjuvant treatment of patients with certain types of non-small cell lung cancer (NSCLC). These results were presented during the Plenary Session at the 2023 ASCO Annual Meeting (abstract #LBA3).
AccessHope – Bridging the Gap in Cancer Treatment Disparities
Mark Stadler, CEO of AccessHope discusses cancer care and why access to the best cancer facilities is out of reach for the majority of Americans, particularly those impacted by social determinants of health (SDOH). He talks about bridging the gap in cancer treatment disparities, empowering community oncologists and how employers can support employees with cancer beyond the initial diagnosis and throughout their entire care journey with personalized solutions that treat the whole person.
How Warmer Weather Affects Psoriasis & Tips to Help Those Impacted
Board-Certified Dermatologist, Dr. Melinda Greenfield discusses plaque psoriasis and how moderate-to-severe plaque psoriasis patients can make the most of warm weather. She talks about treatment options, some things her patients have found helpful in managing their symptoms, and what a patient struggling with moderate-to-severe plaque psoriasis should do. For more information visit www.ilumya.com
2023 ASCO – Astellas – Oncology Development
Dr. Ahsan Arozullah, MD, MPH, Senior Vice President, Head of Oncology Development at Astellas discusses the company’s presence at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. He talks about the expanding portfolio of approved and investigational cancer therapies and how the research underscores the company’s focus on pursuing targeted therapies for hard-to-treat cancers where few therapies exist.